DE2352910A1 - Waessrige pharmazeutische zusammensetzung - Google Patents
Waessrige pharmazeutische zusammensetzungInfo
- Publication number
- DE2352910A1 DE2352910A1 DE19732352910 DE2352910A DE2352910A1 DE 2352910 A1 DE2352910 A1 DE 2352910A1 DE 19732352910 DE19732352910 DE 19732352910 DE 2352910 A DE2352910 A DE 2352910A DE 2352910 A1 DE2352910 A1 DE 2352910A1
- Authority
- DE
- Germany
- Prior art keywords
- doxycycline
- water
- salt
- magnesium
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 claims description 44
- 229960003722 doxycycline Drugs 0.000 claims description 26
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical group [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 10
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical group Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 claims description 8
- 229960004082 doxycycline hydrochloride Drugs 0.000 claims description 8
- 229910000318 alkali metal phosphate Inorganic materials 0.000 claims description 6
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 239000001755 magnesium gluconate Substances 0.000 claims description 3
- 229960003035 magnesium gluconate Drugs 0.000 claims description 3
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 3
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 3
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- 229940005740 hexametaphosphate Drugs 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 claims description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000126 substance Substances 0.000 description 11
- 235000010323 ascorbic acid Nutrition 0.000 description 10
- 239000011668 ascorbic acid Substances 0.000 description 10
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 10
- 235000019799 monosodium phosphate Nutrition 0.000 description 10
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 10
- 229960005070 ascorbic acid Drugs 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 2
- -1 hydrochlorides Chemical class 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940069417 doxy Drugs 0.000 description 1
- 229960001172 doxycycline hyclate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- BBRZBPOCCPEBBU-UHFFFAOYSA-L magnesium;dichloride;hydrochloride Chemical compound [Mg+2].Cl.[Cl-].[Cl-] BBRZBPOCCPEBBU-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000010181 polygamy Effects 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30123672A | 1972-10-26 | 1972-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2352910A1 true DE2352910A1 (de) | 1974-05-09 |
Family
ID=23162536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732352910 Ceased DE2352910A1 (de) | 1972-10-26 | 1973-10-22 | Waessrige pharmazeutische zusammensetzung |
Country Status (17)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0052404B1 (en) * | 1980-11-19 | 1987-05-27 | THE PROCTER & GAMBLE COMPANY | Non-yellowing topical pharmaceutical composition |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5124317A (en) | 1985-08-02 | 1992-06-23 | Farmitalia Carlo Erba S.P.A. | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| CN115844842B (zh) * | 2022-12-28 | 2024-09-13 | 江西省保灵动物保健品有限公司 | 一种盐酸多西环素片剂及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1767891C3 (de) * | 1968-06-28 | 1980-10-30 | Pfizer | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat |
| ES396132A1 (es) * | 1970-10-30 | 1972-12-01 | Villax | Proceso de preparacion de los complejos del acido metafos- forico de la alfa-6-deoxi-5-hidroxitetraciclina y las sales alcali-metalicas de los mismos. |
-
1972
- 1972-12-27 GB GB5971072A patent/GB1350196A/en not_active Expired
-
1973
- 1973-10-16 CA CA183,513A patent/CA1005760A/en not_active Expired
- 1973-10-16 IE IE1845/73A patent/IE38383B1/xx unknown
- 1973-10-19 BE BE1005441A patent/BE806261A/xx not_active IP Right Cessation
- 1973-10-19 FR FR7337347A patent/FR2204402B1/fr not_active Expired
- 1973-10-22 DE DE19732352910 patent/DE2352910A1/de not_active Ceased
- 1973-10-22 PH PH15133*UA patent/PH9547A/en unknown
- 1973-10-23 ZA ZA738187A patent/ZA738187B/xx unknown
- 1973-10-23 CH CH1495773A patent/CH583563A5/xx not_active IP Right Cessation
- 1973-10-24 FI FI3299/73A patent/FI52269B/fi active
- 1973-10-24 NL NL7314596.A patent/NL162836C/xx not_active IP Right Cessation
- 1973-10-25 AR AR250701A patent/AR200582A1/es active
- 1973-10-25 JP JP11949073A patent/JPS531815B2/ja not_active Expired
- 1973-10-25 DK DK578073A patent/DK133084C/da active
- 1973-10-25 SE SE7314529A patent/SE411424B/sv unknown
-
1975
- 1975-09-15 KE KE2568*UA patent/KE2568A/xx unknown
- 1975-12-30 MY MY201/75A patent/MY7500201A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE411424B (sv) | 1979-12-27 |
| BE806261A (fr) | 1974-04-19 |
| FI52269B (enrdf_load_stackoverflow) | 1977-05-02 |
| IE38383L (en) | 1974-04-26 |
| GB1350196A (en) | 1974-04-18 |
| CH583563A5 (enrdf_load_stackoverflow) | 1977-01-14 |
| MY7500201A (en) | 1975-12-31 |
| FR2204402B1 (enrdf_load_stackoverflow) | 1976-08-13 |
| JPS531815B2 (enrdf_load_stackoverflow) | 1978-01-23 |
| NL7314596A (enrdf_load_stackoverflow) | 1974-05-01 |
| CA1005760A (en) | 1977-02-22 |
| NL162836B (nl) | 1980-02-15 |
| JPS4980226A (enrdf_load_stackoverflow) | 1974-08-02 |
| KE2568A (en) | 1975-09-26 |
| ZA738187B (en) | 1974-11-27 |
| DK133084B (da) | 1976-03-22 |
| AU6158973A (en) | 1975-04-24 |
| DK133084C (da) | 1976-08-16 |
| IE38383B1 (en) | 1978-03-01 |
| PH9547A (en) | 1976-01-16 |
| AR200582A1 (es) | 1974-11-22 |
| NL162836C (nl) | 1980-07-15 |
| FR2204402A1 (enrdf_load_stackoverflow) | 1974-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1767891C3 (de) | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat | |
| DE69000645T2 (de) | Bei kuehlschranktemperatur stabile waessrige folinatloesung sowie verfahren zu deren herstellung. | |
| DE1417343A1 (de) | Verfahren zur Herstellung einer antibiotechnischen Zusammensetzung | |
| DE2817335B2 (de) | Stabiles Antibiotisches tetracyclinhaltiges Mittel | |
| DE3437232A1 (de) | Stabilisierte injektionsloesungen von piroxicam | |
| DE69218557T2 (de) | Stabile Zusammensetzung die ein Enalapril-Salz enthält, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2602030C2 (de) | Diphosphonoalkancarbonsäuren und Verfahren zu deren Herstellung | |
| DE2352910A1 (de) | Waessrige pharmazeutische zusammensetzung | |
| DE1802162A1 (de) | Neue N-Pyridylmethyliden-homocystein-thiolacton-Verbindung und Verfahren zu ihrer Herstellung | |
| DE69703994T2 (de) | Parenteral injizierbare Lösungen enthaltend Piroxicam | |
| DE2042323A1 (de) | Blutbildendes Präparat | |
| DE2233747A1 (de) | Bestaendige waessrige doxycyclinloesung | |
| DE2301444C3 (enrdf_load_stackoverflow) | ||
| DE2304705A1 (de) | Nahrungsergaenzungsmittelzubereitung | |
| DE1053734B (de) | Verfahren zur Loeslichmachung und Stabilisierung der Tetracyclinantibiotika | |
| DE2754882A1 (de) | Pharmazeutische zusammensetzungen | |
| DE835926C (de) | Verfahren zur Herstellung von waessrigen Lactoflavinloesungen | |
| DE899702C (de) | Verfahren zur Herstellung von Penicillinloesungen mit langdauernder Wirkung | |
| DE1767957C3 (de) | Herstellung von pulverfötmigen 3,5-Dinitro-o-toluylsäureamid enthaltenden Zusammensetzungen | |
| DE862341C (de) | Verfahren zur Herstellung von waessrigen Loesungen von Derivaten des p-Aminobenzolsulfonamids | |
| DE259826C (enrdf_load_stackoverflow) | ||
| DE934664C (de) | Verfahren zur Herstellung von Proteohormonverbindungen | |
| DE2338901C2 (de) | Pharmazeutisches Präparat mit analgetischer Wirkung | |
| DE1300628B (de) | Antibiotische wasserloesliche Arzneimittelzubereitung von Tetracyclin und Verfahren zu ihrer Herstellung | |
| DE653323C (de) | Verfahren zur Herstellung oelhaltiger verpressbarer Massen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8131 | Rejection |